Thyrocare Technologies Ltd
Q1 FY24 Earnings Call Analysis
Healthcare Services
fundraise: No informationcapex: Yesrevenue: Category 3margin: Category 3orderbook: No information
📊revenue
Future growth expectations in sales/revenue/volumes?
- FY25 growth guidance targets mid-teen revenue growth of 15%-18% (Alok Jagnani).
- Franchisee business expected to return to high teens growth rate post stabilization of small franchisee churn.
- Partnership business excluding API and B2G expected to continue strong growth, leveraging hospital and insurance segment expansions.
- Volume growth: Core franchise business grew 8% in FY24 (year-on-year) with 10% quarter-on-quarter sample growth.
- Focus on geographic expansion deeper into India, enhanced service offerings (e.g., ECG at home via Think Health acquisition).
- Marketing investments continue to promote new packages like JAANCH and Her Check driving brand growth.
- New international market entry: Tanzania launch anticipated to open significant affordable testing opportunities.
- Expect revenue growth driven by a mix shift towards larger franchisees and strategic partnerships, not just price increases.
- Promotion costs and new initiatives investment to sustain growth momentum.
📈margin
Future growth expectations in earnings/operating earnings/profits/EPS?
- FY25 growth strategy focuses on expanding core franchise business by deepening penetration in new cities and geographies.
- Increased focus on partnership business, especially targeting large hospital accounts and insurance sectors, enhanced by ECG capabilities through Think Health acquisition.
- Revenue growth guidance for FY25: mid-teen growth expected (15%-18%), improving from FY24's 9% growth.
- Franchisee business expected to return to high teens growth, driven by stabilization and growth in large franchisees.
- Normalized EBITDA margins expected to be stable around 28%-29%; reported EBITDA margins may improve as ESOP charges reduce.
- Margins to remain flat due to ongoing investments in Tanzania, Think Health, and other expansion efforts.
- Marketing and business promotion spends for FY25 will remain at current levels with no major incremental spend.
- Overall, the company anticipates steady earnings and operating profit growth supported by increased volume, deeper market penetration, and strategic partnerships.
📋orderbook
Current/ Expected Orderbook/ Pending Orders?
The transcript does not explicitly mention current or expected orderbook or pending orders details. However, relevant insights related to business outlook and growth include:
- Focus on expanding franchise business deeper into India and strengthening core franchise and partnership models.
- Emphasis on growing large franchisees, which contribute 90% of franchise revenue.
- Partnership business excluding B2G and API showed strong growth (23% for the year, 40% in Q4).
- New initiatives include expansion in Tanzania and scaling up Think Health (ECG at Home).
- Government business focus shifted to niche areas like TB and infectious diseases with screening partnerships.
- Marketing spends (Rs. 8-10 crores for FY24) targeted promotional projects like JAANCH and Hitech branding to bolster growth.
- No specific numeric order backlog or pending orders disclosed in the call.
💰fundraise
Any current/future new fundraising through debt or equity?
- There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript.
- A question was raised about promoters' pledged shares and recent fundraise, but no specific details on new fundraising plans were disclosed.
- The company discussed ongoing investments in marketing, new business expansions (e.g., Tanzania, Think Health), but funding sources were not detailed.
- ESOPs are in place as a talent retention mechanism, recorded as expenses but not cash outflows.
- Overall, the management focused on organic growth and strategic investments without indicating plans for fresh debt or equity issuance.
🏗️capex
Any current/future capex/capital investment/strategic investment?
- Thyrocare is investing in geographic expansion, including a new venture in Tanzania, aiming to launch affordable diagnostic tests in that country.
- The company is scaling up Think Health, which provides ECG at home services, enhancing offerings especially for insurance partners.
- They continue investing in quality improvements, expanding reach, and improving turnaround time to maintain best-in-class service.
- Marketing and promotion costs of approximately Rs. 8-10 crores were spent in FY24, mainly to promote new packages and brand JAANCH.
- Investments are also being made in partnerships with hospitals and insurance sectors to drive growth.
- Capex in new initiatives like Tanzania and Think Health may initially impact margins but are expected to deliver long-term operating leverage.
- No specific detailed capital expenditure amounts disclosed beyond marketing spends and startup costs for new initiatives.
